Clinical Trials

Multiple clinical trials are currently recruiting to evaluate the biomarker and pathophysiological relevance of ribonucleic acid in mild allergic asthma and spastic cerebral palsy. Sponsored by academic and research institutions, these studies lack standard numerical phase designations and are formally documented as unassigned or Not Applicable. Overall, these investigations aim to monitor inflammatory dynamics and metabolic dysregulation to establish non-invasive measures in respiratory and neuromuscular pathologies.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06317909 Recruiting
Mild Allergic Asthma
Fraunhofer-Institute of Toxicology and Experimental Medicine
2024-06-01 Not Applicable
NCT06330922 Recruiting
Cerebral Palsy Spastic
University of Graz|Medical University of Graz|Karolinska Institutet
2024-03-08 --

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Ribonucleic acid product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Ribonucleic acid serves as a primary biological substrate that binds to ribonuclease enzymes to facilitate the hydrolytic cleavage of phosphodiester bonds within transcript backbones. This catalytic degradation regulates cellular messenger RNA abundance and downstream protein synthesis, thereby modulating active inflammatory mediator signaling in inflammatory and neuromuscular conditions like mild allergic asthma and spastic cerebral palsy.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.